Compare MSAI & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MSAI | GDTC |
|---|---|---|
| Founded | 1995 | 2018 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.6M | 10.4M |
| IPO Year | 2021 | 2021 |
| Metric | MSAI | GDTC |
|---|---|---|
| Price | $5.14 | $0.91 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $110.00 | N/A |
| AVG Volume (30 Days) | 21.3K | ★ 23.5K |
| Earning Date | 05-14-2026 | 04-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 71.03 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,551,000.00 | N/A |
| Revenue This Year | $98.45 | N/A |
| Revenue Next Year | $38.89 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.15 | $0.68 |
| 52 Week High | $7.94 | $3.68 |
| Indicator | MSAI | GDTC |
|---|---|---|
| Relative Strength Index (RSI) | 43.99 | 47.94 |
| Support Level | $4.43 | $0.72 |
| Resistance Level | $5.85 | $1.08 |
| Average True Range (ATR) | 0.38 | 0.09 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 5.45 | 50.99 |
MultiSensor AI Holdings Inc builds and deploys integrated condition monitoring and early threat detection solutions through a unified edge-to-cloud software architecture, delivering AI-powered connected intelligence and analytics for asset reliability and performance. The Company's platform integrates multiple sensing modalities such as thermal, visual, and vibration to detect mechanical, electrical, and other modes of asset failure, enabling organizations operating high-throughput, automation-rich, and power-dense facilities to protect uptime, enhance safety, and extend the useful life of their critical assets.
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.